Akebia Therapeutics (AKBA) Assets Average (2014 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Assets Average data on file, last reported at $369.5 million in Q1 2026.

• Assets Average for Q1 2026 came in at $369.5 million, up 39.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $369.5 million (up 39.23% YoY), and the FY2025 annual result was $298.6 million, up 29.17% from the prior year.
• Assets Average steadied at $369.5 million in Q1 2026 per AKBA's latest filing, from $370.4 million in the prior quarter.
• Over five years, Assets Average peaked at $535.8 million in Q2 2022 and troughed at $213.7 million in Q3 2024.
• A 5-year average of $329.4 million and a median of $318.5 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average tumbled 50.11% in 2023, then surged 73.14% in 2025.
• A 5-year view of Assets Average shows it stood at $400.2 million in 2022, then tumbled by 40.44% to $238.4 million in 2023, then fell by 10.26% to $213.9 million in 2024, then surged by 73.14% to $370.4 million in 2025, then fell by 0.22% to $369.5 million in 2026.
• Business Quant data shows AKBA's Assets Average at $369.5 million in Q1 2026, $370.4 million in Q4 2025, and $354.9 million in Q3 2025.